ResearcherUniversité de BordeauxActive in the last 2 years
Sandrine Dabernat
Matched on ORCID iD 0000-0001-8372-9945; OpenAlex author ID A5000592480. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 6)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 9
- Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects. Last author DOI 10.1245/s10434-025-17062-w↗
- Integrating allele-specific PCR with CRISPR-Cas13a for sensitive KRAS mutation detection in pancreatic cancer. Last author DOI 10.1186/s13036-024-00450-3↗
- KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Last author DOI 10.1038/s41598-022-07004-x↗
- FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Co-author DOI 10.1016/j.dld.2019.03.004↗
- CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.tranon.2019.07.009↗
- Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11060852↗
- High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Su… Co-author DOI 10.3390/cancers11111656↗
- Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Last author DOI 10.1016/j.canlet.2017.01.002↗
- In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Last author DOI 10.1186/1476-4598-11-81↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christophe Laurent · 5 shared papers, 2019–2025 · strength 0.68
- Paper Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects. DOI 10.1245/s10434-025-17062-w↗
- Paper KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predict… DOI 10.1038/s41598-022-07004-x↗
- Paper FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study fro… DOI 10.1016/j.dld.2019.03.004↗
- Samuel Amintas · 3 shared papers, 2022–2025 · strength 0.64
- Paper Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects. DOI 10.1245/s10434-025-17062-w↗
- Paper Integrating allele-specific PCR with CRISPR-Cas13a for sensitive KRAS mutation detection in pancreatic cancer. DOI 10.1186/s13036-024-00450-3↗
- Paper KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predict… DOI 10.1038/s41598-022-07004-x↗
- Étienne Buscail · 6 shared papers, 2017–2022 · strength 0.56
- Paper KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predict… DOI 10.1038/s41598-022-07004-x↗
- Paper Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11060852↗
- Paper FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study fro… DOI 10.1016/j.dld.2019.03.004↗
- L. Chiche · 5 shared papers, 2019–2022 · strength 0.49
- Paper KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predict… DOI 10.1038/s41598-022-07004-x↗
- Paper Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11060852↗
- Paper FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study fro… DOI 10.1016/j.dld.2019.03.004↗
- Mehdi Boubaddi · 2 shared papers, 2024–2025 · strength 0.48
- V. Vendrely · 4 shared papers, 2017–2019 · strength 0.30
- Paper FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study fro… DOI 10.1016/j.dld.2019.03.004↗
- Paper CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenoc… DOI 10.1016/j.tranon.2019.07.009↗
- Paper High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocar… DOI 10.3390/cancers11111656↗
- Arthur Marichez · 1 shared paper, 2025 · strength 0.28
- Catherine Alix‐Panabières · 2 shared papers, 2019 · strength 0.18
- Fabrice Muscari · 1 shared paper, 2019 · strength 0.10
- Charlotte Maulat · 1 shared paper, 2019 · strength 0.10
- Louis Buscail · 1 shared paper, 2019 · strength 0.10
- Pierre Cordelier · 1 shared paper, 2019 · strength 0.10
- Claudia Pouypoudat · 1 shared paper, 2019 · strength 0.08
- Christophe Cassinotto · 1 shared paper, 2019 · strength 0.08
- Jean‐Frédéric Blanc · 1 shared paper, 2019 · strength 0.08
- Marie Lafitte · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.